Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.
about
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in miceRole of LRRK2 in the regulation of dopamine receptor traffickingLRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit functionThe function of orthologues of the human Parkinson's disease gene LRRK2 across species: implications for disease modelling in preclinical research.Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.Initial elevations in glutamate and dopamine neurotransmission decline with age, as does exploratory behavior, in LRRK2 G2019S knock-in micePAK6 Phosphorylates 14-3-3γ to Regulate Steady State Phosphorylation of LRRK2.Abnormal visual gain control and excitotoxicity in early-onset Parkinson's disease Drosophila models.Targeted kinase inhibition relieves slowness and tremor in a Drosophila model of LRRK2 Parkinson's disease.Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.Prediction and characterization of human ageing-related proteins by using machine learning.Small-Molecule Inhibitors of LRRK2.Overexpression of Wild-Type Human Alpha-Synuclein Causes Metabolism Abnormalities in Thy1-aSYN Transgenic Mice
P2860
Q27308060-F6848D72-9E12-42A3-BA03-38FCA2517EACQ33764887-D4B77080-5ADB-4960-85B0-16515E33F155Q36581417-74C68F88-4CA2-4675-BC2F-C2E5943ABBAEQ37513500-815B16B0-C7F7-4B48-B2B6-EF8181DB2189Q37701053-2BBFEC1E-65BC-4172-9144-451EE60DBC0DQ42268862-23B3AB07-825A-4027-9F70-592F60BCA231Q47222316-401DBAAB-4BC5-47DD-835B-DED4E7A5781AQ47590441-85809C54-C566-4481-B66A-19C84FA63B36Q48163602-F03D1A12-BB51-4A51-BD41-A5CB37B9A419Q50055669-54F58F8B-9AF6-4860-B3C4-1585EEC78F84Q50420614-98D59D18-815B-4C9C-A643-A0F02C99CACCQ51082140-3B4EA05F-C3B4-4386-9A02-E69A66A25D96Q58586715-AB1BD8B1-821D-437C-BFCB-B8D1C76011F2
P2860
Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging.
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Genetic and pharmacological ev ...... decline associated with aging.
@ast
Genetic and pharmacological ev ...... decline associated with aging.
@en
Genetic and pharmacological ev ...... decline associated with aging.
@nl
type
label
Genetic and pharmacological ev ...... decline associated with aging.
@ast
Genetic and pharmacological ev ...... decline associated with aging.
@en
Genetic and pharmacological ev ...... decline associated with aging.
@nl
prefLabel
Genetic and pharmacological ev ...... decline associated with aging.
@ast
Genetic and pharmacological ev ...... decline associated with aging.
@en
Genetic and pharmacological ev ...... decline associated with aging.
@nl
P2860
P50
P1476
Genetic and pharmacological ev ...... decline associated with aging.
@en
P2093
Elisa Greggio
Michele Morari
P2860
P356
10.1016/J.NBD.2014.07.013
P577
2014-08-06T00:00:00Z